ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

MicroRNA Agomir Synthesis: Supporting New Drug Research with Cutting-Edge Chemical Synthesis Technology

By: Get News
Creative Biogene announced the release of its microRNA agomir synthesis services which can be applied to support new drug research with cutting-edge chemical synthesis technology.

New York, USA – July 29, 2022 – Creative Biogene, a scientists-founded and scientists-driven leading biotechnological company, focuses on developing high quality products and services to accelerate the research pace in the field of biomedical development, industrial synthetic application and preclinical drug discovery. Recently, Creative Biogene announced the release of its microRNA agomir synthesis services which can be applied to support new drug research with cutting-edge chemical synthesis technology.

Creative Biogene is committed to providing superior miRNA products and comprehensive services to facilitate and simplify miRNA research. Creative Biogene provides agomir/antagomir synthesis services covering all human, mouse and rat miRNAs currently in miRBase. They are synthetic RNA molecules developed for the study of miRNA function in vivo.

Creative Biogene’s micro DOWN™ miRNA antagomirs are single-stranded miRNA inhibitors that exert chemical modifications by effectively blocking miRNA regulation of target gene expression. The chain of antagomir has 2 phosphorothioates at the 5′ end, 4 phosphorothioates at the 3′ end, a cholesterol group, and a full-length nucleotide 2′-methoxy modification. The micro DOWN™ miRNA antagomir appears to be significantly more stable than miRNA inhibitors. It exhibits enhanced cellular uptake, stability, and regulatory activity and is recommended for in vitro and in vivo miRNA functional studies.

Creative Biogene’s micro UP™ miRNA agomirs are designed to mimic mature miRNAs and chemically modified to increase their stability and activity. They are recommended for in vitro and in vivo miRNA functional studies.

MicroRNAs incompletely pair with the target messenger RNAs (mRNAs) of protein-coding genes and regulate their expression transcriptionally or post-transcriptionally to participate in key biological processes, including development, differentiation, apoptosis, and proliferation. Creative Biogene’s miRNAs Agomir and Antagomir can be efficiently enriched in target cells to achieve specific and stable interference, so Agomir/Antagomir transfection of cells and animal injection are two major research applications. miRNA Agomir/Antagomir are for research use only, but these advanced products still have practical implications for research in clinical trials, cancer therapy, and gene therapy, as miRNAs are presumed to regulate one-third of human genes.

“Our team has pioneered the development of microRNA research and diagnostic tools with leading service. We are committed to opening new avenues to meet all your needs for miRNA agomir/antagomir synthesis.” said Marcia Brady, the marketing director of Creative Biogene, she also added, “Our experienced team can always provide professional service according to your needs.”

About Creative Biogene

Creative Biogene, as a top-of-its-kind company that holds a leading position and is committed to accelerating the development of human science through biotechnology, offering innovative technologies, products, unique tools and services for research discoveries and product development. With more than 10 years of experience and in-house experts, Creative Biogene has become a well-recognized industry leader to support researchers worldwide.

Media Contact
Company Name: Creative Biogene
Contact Person: Marcia Brady
Email: Send Email
Phone: 1-631-386-8241
Country: United States
Website: https://www.creative-biogene.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.